DTaP Vaccine Market Share, Size, Analysis And Opportunity Assessment (2019 - 2026)

Growing demand for DTaP vaccines to prevent the occurrence of diseases such as diphtheria, tetanus, and pertussis is a significant factor expected to stimulate market growth.

Market Size – USD 2.88 billion in 2018, Market Growth - CAGR of 6.8%, Market Trends – Initiatives taken by governments to eradicate these diseases

The global DTaP Vaccine market is expected to reach USD 5.00 Billion by 2026, according to a new report by Reports and Data. DTaP (Diphtheria, Tetanus and acellular Pertussis) is an immunization product targeting diphtheria, tetanus, and pertussis, and is usually first given at two months of age. The capital letters "D" and "P" in DTaP relate to increased diphtheria and pertussis antigen concentrations, in comparison to Tdap products.

Factors such as high birth rate and the growing popularity of pertussis vaccination, are anticipated to propel the pertussis vaccine market which in turn would have a positive impact on the DTaP vaccine market globally. According to a survey by WHO in 2015, 126 countries had achieved a minimum 90% coverage of the vaccine. Besides, injuries caused by these vaccines is likely to impede the growth of the global market. In the U.S. in 2015, there had been seven claims registered in the federal VICP (Vaccine Injury Compensation Program) on account of post-pertussis vaccination injuries and deaths, comprising three deaths and four serious injuries.

To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/press-release/global-dtap-vaccine-market 

Further key findings from the report suggest

• By disease type, the use of the vaccine in treating Pertussis is anticipated to witness a significant growth rate of 7.0% during the forecast period as childhood vaccination is one of the safest and cost-effective ways for the pertussis-free environment.
• Kinrix is forecasted to hold a significant share of the market with a growth rate of 6.9% during the forecast period.
• The Europe and Asia Pacific markets follow the North America market in terms of market dominance.
• Key participants include GlaxoSmithKline, Sanofi Pasteur, Protein Sciences Corporation, Novartis AG, Merch Sharp & Dohme Corp., Pfizer Inc., Astellas Pharma US, Sanofi Aventis, AstraZeneca, and Emergent Biosolution Inc. among others.

For the purpose of this report, Reports and Data have segmented global DTaP Vaccine market on the basis of disease type, product type, end-user, and region:

Disease Type Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)

• Diphtheria
• Tetanus
• Pertussis

Product Type Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)

• Daptacel
• Infanrix
• Kinrix
• Pediarix
• Pentacel
• Quaracel

End-user Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)

• Hospitals
• Clinics
• Vaccination Centers

Regional Outlook (Volume, Kilo Tons; 2016-2026 and Revenue, USD Million; 2016-2026)

• North America
  1. U.S.
• Europe
  1. UK
  2. France
• Asia Pacific
  1. China
  2. India
  3. Japan
• Latin America
  1. Brazil
• MEA